Myc degradation: dancing with ubiquitin ligases - PubMed (original) (raw)

Comment

Myc degradation: dancing with ubiquitin ligases

Bruno Amati. Proc Natl Acad Sci U S A. 2004.

No abstract available

PubMed Disclaimer

Figures

Fig. 1.

Emergence of a “Myc modification cycle” regulating protein turnover and activity. (A) Structure of Myc and Max. (B) A series of posttranslational modifications in MB1 regulates Myc's interactions with ubiquitin ligases and may impact its transcriptional activities. Question marks indicate unresolved or hypothetical connections.

Comment on

• The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.
  Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, Clurman BE. Welcker M, et al. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90. doi: 10.1073/pnas.0402770101. Epub 2004 May 18. Proc Natl Acad Sci U S A. 2004. PMID: 15150404 Free PMC article.

Similar articles

• Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells.
  Chen XM, Xie XB, Zhao Q, Wang F, Bai Y, Yin JQ, Jiang H, Xie XL, Jia Q, Huang G. Chen XM, et al. Mol Med Rep. 2015 Jan;11(1):105-12. doi: 10.3892/mmr.2014.2733. Epub 2014 Oct 21. Mol Med Rep. 2015. PMID: 25333250 Free PMC article.
• MM-1 facilitates degradation of c-Myc by recruiting proteasome and a novel ubiquitin E3 ligase.
  Kimura Y, Nagao A, Fujioka Y, Satou A, Taira T, Iguchi-Ariga SM, Ariga H. Kimura Y, et al. Int J Oncol. 2007 Oct;31(4):829-36. Int J Oncol. 2007. PMID: 17786314
• SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.
  Bretones G, Acosta JC, Caraballo JM, Ferrándiz N, Gómez-Casares MT, Albajar M, Blanco R, Ruiz P, Hung WC, Albero MP, Perez-Roger I, León J. Bretones G, et al. J Biol Chem. 2011 Mar 18;286(11):9815-25. doi: 10.1074/jbc.M110.165977. Epub 2011 Jan 18. J Biol Chem. 2011. PMID: 21245140 Free PMC article.
• Implication of the ubiquitin/proteasome system in Myc-regulated transcription.
  von der Lehr N, Johansson S, Larsson LG. von der Lehr N, et al. Cell Cycle. 2003 Sep-Oct;2(5):403-7. Cell Cycle. 2003. PMID: 12963825 Review.
• Ubiquitination of Myc: proteasomal degradation and beyond.
  Müller J, Eilers M. Müller J, et al. Ernst Schering Found Symp Proc. 2008;(1):99-113. doi: 10.1007/2789_2008_103. Ernst Schering Found Symp Proc. 2008. PMID: 19198066 Review.

Cited by

• PIAS family in cancer: from basic mechanisms to clinical applications.
  Li X, Rasul A, Sharif F, Hassan M. Li X, et al. Front Oncol. 2024 Mar 25;14:1376633. doi: 10.3389/fonc.2024.1376633. eCollection 2024. Front Oncol. 2024. PMID: 38590645 Free PMC article. Review.
• Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear lncRNA function and effective cancer therapy.
  Huang Z, Liu S, Lu N, Xu L, Shen Q, Huang Z, Huang Z, Saw PE, Xu X. Huang Z, et al. Exploration (Beijing). 2022 Jul 26;2(5):20220013. doi: 10.1002/EXP.20220013. eCollection 2022 Oct. Exploration (Beijing). 2022. PMID: 37325502 Free PMC article.
• Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments.
  Ferraiuolo RM, Fifield BA, Hamm C, Porter LA. Ferraiuolo RM, et al. Breast Cancer Res Treat. 2022 Nov;196(1):17-30. doi: 10.1007/s10549-022-06715-z. Epub 2022 Aug 27. Breast Cancer Res Treat. 2022. PMID: 36029387
• The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.
  Liu C, Qian L, Vallega KA, Ma G, Zong D, Chen L, Wang S, Ramalingam SR, Qin Z, Sun SY. Liu C, et al. Am J Cancer Res. 2022 Feb 15;12(2):779-792. eCollection 2022. Am J Cancer Res. 2022. PMID: 35261801 Free PMC article.

References

1. 1. Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N. & Clurman, B. E. (2004) Proc. Natl. Acad. Sci. USA 101, 9085–9090. - PMC - PubMed
2. 1. Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K. & Nakayama, K. I. (2004) EMBO J., in press. - PMC - PubMed
3. 1. Moberg, K. H., Mukherjee, A., Veraksa, A., Artavanis-Tsakonas, S. & Hariharan, I. K. (2004) Curr. Biol., in press.. - PubMed
4. 1. Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) Nat. Cell Biol. 6, 308–318. - PubMed
5. 1. Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E. & Tansey, W. P. (2003) Mol. Cell 11, 1177–1188. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • FlyBase